ConductScience.org, home

Comparison · NCT03918629-deaths

2-Dose Clostridium Difficile Vaccine vs 3-Dose Clostridium Difficile Vaccine: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. 2-Dose Clostridium Difficile Vaccine vs 3-Dose Clostridium Difficile Vaccine: deaths from any cause. Trial comparisons, record NCT03918629-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03918629-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.01510.009170.0247wilson
Risk in group 20.007020.003410.0144wilson
Risk difference, group 1 minus group 20.00807-0.001410.0184newcombe hybrid score
Risk ratio, group 1 over group 22.150.885.25log
Odds ratio, group 1 over group 22.170.885.34log
Number needed to harm, for one more death from any cause on 2-Dose Clostridium Difficile Vaccine than on 3-Dose Clostridium Difficile Vaccine124from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 12-Dose Clostridium Difficile Vaccine
Participants received 1 dose of toxin-based Clostridium difficile vaccine intramuscularly at visit 1 (Month 0) and visit 4 (Month 6) and 1 dose of placebo (0.9% sodium chloride) at visit 2 (Month 1). Participants were followed up to 6 months after last dose of vaccination at Month 6.
15994EG000
Group 23-Dose Clostridium Difficile Vaccine
Participants received 1 dose of toxin-based Clostridium difficile vaccine intramuscularly at visit 1 (Month 0), visit 2 (Month 1), and visit 4 (Month 6). Participants were followed up to 6 months after last dose of vaccination at Month 6.
7997EG001

Harm

What it counts
Total, all-cause mortality
Time frame
Local reactions and systemic events: within 7 days after vaccination (systematic assessment), other AEs: from Day 1 up to 1 month after last dose of vaccination (up to Month 7), all-cause mortality and SAEs: from Day 1 up to 6 months after last dose of vaccination (up to Month 12)

Source ClinicalTrials.gov

Trial

Title
Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study
NCT number
NCT03918629
Phases
PHASE3
Conditions
Clostridium Difficile Associated Disease
Interventions
Clostridium difficile, Placebo
Lead sponsor
Pfizer
Results first posted
2024-01-10

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03918629-deaths